High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure

M Pecherstorfer, I Zimmer-Roth, S Weidinger, K Irsigler, W M Halbmayer, W Ulrich, M Fischer, G Baumgartner

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Artikel in Fachzeitschrift

11 Zitate (Scopus)


A kappa light-chain myeloma was diagnosed as the underlying disease in a 52-year-old woman with acute oliguric renal failure. The patient was erroneously treated with high-dose intravenous melphalan (60 mg/m2). Because of this overdose treatment with granulocyte colony-stimulating factor was initiated, but pronounced absolute leukopenia (white blood cell count < 0.5 x 10(9)/l) developed and lasted for 13 days. Following melphalan treatment a continuous increase in urine volume was accompanied by a decrease of serum creatinine and blood urea nitrogen. Within 10 days after the administration of melphalan the patient no longer required hemodialysis. We conclude that high-dose chemotherapy in combination with hematopoietic growth factors should be considered in individual cases with newly diagnosed light-chain nephropathy.

Seiten (von - bis)522-5
FachzeitschriftJournal of Molecular Medicine
PublikationsstatusVeröffentlicht - Juli 1994
Extern publiziertJa


Untersuchen Sie die Forschungsthemen von „High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren